Tech Company M&A Transactions
Pearl Therapeutics Acquisition
On 6/10/2013, Pearl Therapeutics was purchased by AstraZeneca. AstraZeneca disclosed that the acquisition price was $1.2 billion.
Transaction Overview
Company Name
Acquired By
Announced On
6/10/2013
Transaction Type
M&A
Amount
$1,150,000,000
M&A Terms
Astra agreed to pay $560 million upfront for Pearl, plus up to $450 million in milestone payments if products in development progress successfully, and as much as $140 million in sales payments if the drugs meet certain sales thresholds.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Saginaw Drive
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Pearl Therapeutics is focused on developing a pipeline of novel andsuperior products for chronic respiratory disorders, providing patientswith advanced therapeutic options in familiar and well accepted dosageforms. The company has licensed advanced particle technology from NektarTherapeutics (Nasdaq: NKTR) for developing a series of products in selectedtherapeutic fields.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles Bramlage
Chief Medical Officer
Colin Reisner
Chief Scientific Officer
Sarvajna Dwivedi
VP - Bus. Development
Lyn Baranowski
VP - Finance
William Picht
VP - Product Management
Robert Schultz
VP - Regulatory Affairs
Michael Golden
Browse more venture capital transactions:
Prev: 6/10/2013: Affinity Solutions venture capital transaction
Next: 6/10/2013: Twilio venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs